The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
about
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.Discovery of novel immunostimulants by dendritic-cell-based functional screening.Toll-like receptor 7 agonist therapy with imidazoquinoline enhances cancer cell death and increases lymphocytic infiltration and proinflammatory cytokine production in established tumors of a renal cell carcinoma mouse model.Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo.Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells.Toll-like receptor modulation in cardiovascular disease: a target for intervention?Protective cancer immunotherapy: what can the innate immune system contribute?Toll-like receptors and immune regulation: implications for cancer therapy.Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness?Guidelines for the management of basal cell carcinoma.The BLyS family: toward a molecular understanding of B cell homeostasis.Imiquimod-induced CCR9 Ameliorates murine TNBS ColitisCancer immunotherapy and nanomedicine.Toll-Like Receptors (TLRs): The Role in Tumor Progression.Toll-like receptors and skin cancer.Intratumoral immunotherapy for melanoma.Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.Bacterial flagellin-a potent immunomodulatory agent.Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.Gardiquimod inhibits the expression of calcium-induced differentiation markers in HaCaT cells.Toll-like receptor-4 agonist inhibits motility and invasion of hepatoblastoma HepG2 cells in vitro.Temporal interleukin-1beta secretion from primary human peripheral blood monocytes by P2X7-independent and P2X7-dependent mechanisms.The effect of imiquimod on matrix metalloproteinases and tissue inhibitors of metalloproteinases in malignant melanoma cell invasion.An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma.Toll-like receptors: role in dermatological disease.A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma.Molecular analysis of the effect of topical imiquimod treatment of HPV 2/27/57-induced common warts.Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice.Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.NeoplasmsStrategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants
P2860
Q34364876-8E680426-476B-4B14-B5E1-4C04A59A1E33Q35058213-8782D515-BCCE-464B-A199-56F32CCC8014Q35724734-77C6F230-DC23-41E4-902D-2F17D74D9BA4Q35848403-647D652C-BFAE-4625-ABC7-6EB099CB25ADQ35865283-91441F6B-C065-4DA3-A8E9-3FC39D629D0FQ35944516-26424EB3-3E24-44A4-A00C-472644F7181FQ36096165-9BECA8F4-D4F8-4011-88F6-F25EBA1BC7BBQ36543054-E10F5D66-CF37-4066-9614-9F2D59BFD702Q37032632-DAA874F6-4735-42F4-AC22-7D60D9A60BFFQ37051007-1D3F50B2-B5D9-4EEE-866A-A3E2ABE62643Q37198685-B782B416-0A8D-471E-8F57-E2AC807ACBDDQ37204336-52C10A63-3B1B-4CDB-B4D3-305FEBFF56AEQ37335169-46D1862D-D741-46A2-B6DC-B0A34C859BEAQ37616805-82D6B8DB-2EFF-4EEC-93BC-596C57B5B89EQ37785836-402A1C87-1EEC-4084-A13A-F0C97829CD0BQ38014847-D041DB52-992A-4000-A635-3CE717BEAA26Q38205438-64B03372-1BC2-4AF6-BCC5-8E8E2C3CAF6AQ38518518-FC584A88-ADAE-4201-A33F-E0FC13D6F5CFQ38602867-D054D5DB-9E36-4543-B36E-F2851E659BCAQ38634734-6843F493-472D-4B06-8AF4-71CAB002C72AQ38726697-B09587A4-741A-4FC0-8BC4-D89299E83C0BQ38947206-2450009F-C853-49A6-9A8C-233ACD591860Q39093045-C2FA1275-0278-4625-86D5-533E6A3ED88FQ39339457-50710D92-EF95-4098-8597-CB84E344749EQ39701214-B72C8C10-9C0B-4FF9-8CA2-69B182EFFBE2Q41124607-7C0B3C30-6EDB-43CB-B6D0-A85DB5E558C8Q41790543-8D2B28AE-6907-4348-9A6E-D32953369FDDQ42431181-E6770A1C-B624-4561-A432-4D7794B8DC7AQ42519836-90FD5E21-BC5C-4B40-9F51-36CFDA815032Q43481126-351E83C0-BF31-4807-B3FA-5F2756B35639Q46946071-1D944640-3E08-4203-89CF-FC93D36703F5Q47159679-8AC3550F-4DD4-406C-A193-34741AE111ECQ53643579-85F86C90-1465-4B40-A559-5059BE648E41Q56828372-46D87A42-27ED-4E80-864C-4D6D82554ED9Q57198394-6AFC3C59-F946-4B7B-BC47-F8BE72827878
P2860
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@ast
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@en
type
label
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@ast
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@en
prefLabel
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@ast
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@en
P2093
P2860
P1476
The use of Toll-like receptor- ...... l cell carcinoma: an overview.
@en
P2093
C Garcia-Bartels
E Stockfleth
P2860
P356
10.1046/J.0366-077X.2003.05626.X
P407
P478
149 Suppl 66
P577
2003-11-01T00:00:00Z